Actively Recruiting

Phase 2
Phase 3
Age: 30Years +
All Genders
ID05517434

Intra-Articular Autologous Bone Marrow Aspirate vs Placebo Injection and Lipoaspirate Micronized with Leukocyte-Poor Platelet Rich Plasma vs Placebo Injection Evaluations for Treatment of Knee Osteoarthritis: The ABLE OA Double-Blinded Randomized Clinical Trial

Led by University Health Network, Toronto · Updated on 2025-12-19

148

Participants Needed

2

Research Sites

26 weeks

Total Duration

On this page

Sponsors

U

University Health Network, Toronto

Lead Sponsor

W

Women's College Hospital

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are evaluating two minimally manipulated autologous cellular treatments for knee osteoarthritis (OA) in a phase II/III multi-center, double-blinded, randomized, placebo-controlled trial. The study compares bone marrow aspirate (BMA) injection and a combination of lipoaspirate micronized (LAM) with leukocyte-poor platelet-rich plasma (LP-PRP) injections against placebo saline injections. The goal is to measure pain improvement and functional outcomes in adults with knee OA. Participants will receive either an intra-articular injection of BMA collected from bone marrow aspiration or an injection of LAM plus LP-PRP prepared from lipoaspirate and whole blood. Each treatment is compared to a placebo saline injection group. Bone marrow aspiration or lipoaspiration plus blood draw are performed before injections. Injections are ultrasound-guided and given as a single dose. Two independent studies are conducted under one protocol, each with a treatment and placebo group. Participants will complete patient-reported outcome questionnaires at baseline, 3, 6, and 12 months post-injection. Biological samples including blood, synovial fluid, and urine will be collected at baseline and 6 months. Safety is monitored through adverse event reporting and X-rays at 6 months. The main outcome is a pain score improvement at 6 months. Other measures include functional scores, health-related quality of life, treatment satisfaction, and health care usage. Total participation lasts up to 12 months post-injection.

CONDITIONS

Brief Title

Autologous BMA vs Saline and LAM + LP-PRP vs Saline Evaluations in Knee OA

Who Can Participate

Age: 30Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male or female at least 30 years of age at the time of screening
  • Willingness and ability to comply with study procedures and visit schedules
  • Signed consent for study participation
  • Baseline Numeric Pain Rating Scale (NPRS) score of 4 points or higher
  • Chronic, symptomatic knee pain in at least one knee; if both knees affected, the more severe knee will be treated
  • Kellgren-Lawrence (KL) grade 2 or 3 knee osteoarthritis based on standing knee X-ray
  • Body mass index (BMI) of 30 kg/m2 or less
Not Eligible

You will not qualify if you...

  • Anti-inflammatory knee injections (including corticosteroids, Synvisc, PRP, nSTRIDE) within the past 6 months
  • Major axial knee deviation (varus or valgus greater than 10 degrees)
  • Knee lesions causing pain or swelling (ligament, meniscus, osteochondral injury)
  • Active infection in the treated knee
  • Diagnosed inflammatory arthritis or related diseases (rheumatoid arthritis, psoriatic arthritis, gout, etc.)
  • Diagnosed blood cancers or ongoing/planned chemotherapy
  • Venous or lymphatic stasis in the treated leg
  • Allergy to local anesthetics
  • Blood clotting disorders such as hemophilia
  • Arthroscopic knee surgery within the past 6 months
  • Daily opioid use for past 3 months or recent NSAID use within 1 week
  • Use of systemic corticosteroids for chronic conditions within past 3 months
  • Immunosuppression or acute infections
  • For Study 1: inability to tolerate bone marrow aspiration or insufficient bone marrow collection after two attempts
  • For Study 2: inability to tolerate lipoaspiration or insufficient lipoaspirate collection after two attempts

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - Single day

Participants receive a single ultrasound guided intra-articular injection after either bone marrow aspiration or lipoaspiration and blood collection, depending on their assigned group.

1 injection visit (in-person)

Follow-up

Duration - 12 months post-injection

Participants are followed to assess pain levels, knee function, safety, and overall satisfaction after injection.

Visits at 3, 6, and 12 months post-injection (in-person or remote)

Trial Site Locations

Total: 2 locations

1

Women's College Hospital

Toronto, Ontario, Canada, M5S 1B2

Not Yet Recruiting

2

Toronto Western Hospital, University Health Network

Toronto, Ontario, Canada, M5T 2S8

Actively Recruiting

Loading map...

Research Team

S

Shoba Singh

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

4

Similar Trials

A Master Protocol for Randomized, Placebo-Controlled Phase 2...

Osteoarthritis, Knee

Actively Recruiting

64 locations

A 48-Weeks, Phase 2b/3a, Double-Blind, Randomized, Placebo C...

Osteoarthritis, Knee

Actively Recruiting

9 locations

A Phase 3, Randomised, Double-Blind, Placebo-Controlled Mult...

Osteoarthritis, Knee

Actively Recruiting

56 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here